These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 29199664)

  • 21. Immune-mediated thrombocytopenia and hypothyroidism in a lung cancer patient treated with nivolumab.
    Jotatsu T; Oda K; Yamaguchi Y; Noguchi S; Kawanami T; Kido T; Satoh M; Yatera K
    Immunotherapy; 2018 Feb; 10(2):85-91. PubMed ID: 29260625
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunotherapeutic strategies in non-small-cell lung cancer: the present and the future.
    Steendam CM; Dammeijer F; Aerts JGJV; Cornelissen R
    Immunotherapy; 2017 May; 9(6):507-520. PubMed ID: 28472903
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting PD-L1 for non-small-cell lung cancer.
    Feld E; Horn L
    Immunotherapy; 2016 Jun; 8(6):747-58. PubMed ID: 27197542
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System.
    Moon EK; Langer CJ; Albelda SM
    Ann Am Thorac Soc; 2017 Aug; 14(8):1248-1260. PubMed ID: 28613923
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-PD-1-related cryoglobulinemia during treatment with nivolumab in NSCLC patient.
    Pellegrino B; Musolino A; Tiseo M
    Ann Oncol; 2017 Jun; 28(6):1405-1406. PubMed ID: 28383638
    [No Abstract]   [Full Text] [Related]  

  • 26. Aprepitant for refractory nivolumab-induced pruritus.
    Ito J; Fujimoto D; Nakamura A; Nagano T; Uehara K; Imai Y; Tomii K
    Lung Cancer; 2017 Jul; 109():58-61. PubMed ID: 28577951
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.
    Kazandjian D; Suzman DL; Blumenthal G; Mushti S; He K; Libeg M; Keegan P; Pazdur R
    Oncologist; 2016 May; 21(5):634-42. PubMed ID: 26984449
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The incidence and relative risk of pulmonary toxicity in patients treated with anti-PD1/PD-L1 therapy for solid tumors: a meta-analysis of current studies.
    Ciccarese C; Iacovelli R; Bria E; Modena A; Massari F; Brunelli M; Fantinel E; Bimbatti D; Zamboni GA; Artibani W; Tortora G
    Immunotherapy; 2017 Jun; 9(7):579-587. PubMed ID: 28595514
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotherapy for non-small cell lung cancer: are we on the cusp of a new era?
    Waqar SN; Morgensztern D
    Expert Rev Clin Immunol; 2015; 11(8):871-3. PubMed ID: 26051156
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.
    Bagley SJ; Kothari S; Aggarwal C; Bauml JM; Alley EW; Evans TL; Kosteva JA; Ciunci CA; Gabriel PE; Thompson JC; Stonehouse-Lee S; Sherry VE; Gilbert E; Eaby-Sandy B; Mutale F; DiLullo G; Cohen RB; Vachani A; Langer CJ
    Lung Cancer; 2017 Apr; 106():1-7. PubMed ID: 28285682
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A New Immunotherapy Drug Creates a Watershed for the Surgical Pathologist's Role in Patient Care.
    Cagle PT; Bernicker EH
    Arch Pathol Lab Med; 2015 Nov; 139(11):1329. PubMed ID: 26516934
    [No Abstract]   [Full Text] [Related]  

  • 32. Role of immunotherapy in the treatment of advanced non-small-cell lung cancer.
    Rijavec E; Genova C; Alama A; Barletta G; Sini C; Pronzato P; Coco S; Dal Bello MG; Savarino G; Truini A; Boccardo F; Grossi F
    Future Oncol; 2014 Jan; 10(1):79-90. PubMed ID: 24328411
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Co-relation of overall survival with peripheral blood-based inflammatory biomarkers in advanced stage non-small cell lung cancer treated with anti-programmed cell death-1 therapy: results from a single institutional database.
    Naqash AR; Stroud CRG; Butt MU; Dy GK; Hegde A; Muzaffar M; Yang LV; Hafiz M; Cherry CR; Walker PR
    Acta Oncol; 2018 Jun; 57(6):867-872. PubMed ID: 29241410
    [No Abstract]   [Full Text] [Related]  

  • 34. Immunotherapy for lung cancer: for whom the bell tolls?
    Madureira P; de Mello RA; de Vasconcelos A; Zhang Y
    Tumour Biol; 2015 Mar; 36(3):1411-22. PubMed ID: 25736929
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
    Brahmer J; Reckamp KL; Baas P; Crinò L; Eberhardt WE; Poddubskaya E; Antonia S; Pluzanski A; Vokes EE; Holgado E; Waterhouse D; Ready N; Gainor J; Arén Frontera O; Havel L; Steins M; Garassino MC; Aerts JG; Domine M; Paz-Ares L; Reck M; Baudelet C; Harbison CT; Lestini B; Spigel DR
    N Engl J Med; 2015 Jul; 373(2):123-35. PubMed ID: 26028407
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches.
    Remon J; Pardo N; Martinez-Martí A; Cedrés S; Navarro A; Martinez de Castro AM; Felip E
    Lung Cancer; 2017 Apr; 106():70-75. PubMed ID: 28285697
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Non-small cell lung cancer: news from immunotherapy].
    Reinmuth N; Heigener DF; Reck M
    Dtsch Med Wochenschr; 2015 Mar; 140(5):329-33. PubMed ID: 25734674
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nivolumab: a review in advanced squamous non-small cell lung cancer.
    Keating GM
    Drugs; 2015 Nov; 75(16):1925-34. PubMed ID: 26514815
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.
    Rizvi NA; Mazières J; Planchard D; Stinchcombe TE; Dy GK; Antonia SJ; Horn L; Lena H; Minenza E; Mennecier B; Otterson GA; Campos LT; Gandara DR; Levy BP; Nair SG; Zalcman G; Wolf J; Souquet PJ; Baldini E; Cappuzzo F; Chouaid C; Dowlati A; Sanborn R; Lopez-Chavez A; Grohe C; Huber RM; Harbison CT; Baudelet C; Lestini BJ; Ramalingam SS
    Lancet Oncol; 2015 Mar; 16(3):257-65. PubMed ID: 25704439
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Understanding immunotherapy for the treatment of non-small cell lung cancer.
    Thomas R
    Br J Nurs; 2016 Sep; 25(16):S12-7. PubMed ID: 27615536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.